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Abstract
Purpose: Clinical pharmacists can help primary care physicians (PCPs) manage medi-
cations for patients with poorly controlled type 2 diabetes. Studies have shown that
clinical pharmacist involvement in care can improve outcomes such as glycosylated
hemoglobin (A1C), blood pressure and lipid control, and decrease episodes of hypo-
glycemia. Despite these findings, some PCPs may be slow or disinclined to refer to
clinical pharmacists when available. This study addressed PCP perceptions regarding
referral to clinical pharmacists and endocrinologists for patients with poorly con-
trolled type 2 diabetes.
Methods: Physicians from five family medicine sites were surveyed. Physicians were
queried regarding their patterns for patient referral to endocrinologists and/or clinical
pharmacists. Clinical contributions and importance of factors to consider when refer-
ring were compared between clinical pharmacists and endocrinologists using paired
t tests.
Results: Fifty physicians responded to the survey, resulting in a response rate of
73.5%. The majority of PCPs indicated that they have referred to endocrinologists
(89.5%) and clinical pharmacists (93.5%) for specialty care. PCPs tended to refer to
clinical pharmacists sooner and at lower A1C values than to endocrinologists. PCPs
also considered multiple medical comorbidities, history of noncompliance with medi-
cal recommendations, low reading ability or math skills, complex psychosocial situa-
tions, fear of needles, or difficulty affording medications or supplies to be more
important when referring patients to clinical pharmacists than endocrinologists.
Conclusion: We hypothesized that referrals to a clinical pharmacist or endocrinolo-
gist are made with careful consideration of the patients' needs. PCPs reported
increased utilization of clinical pharmacists for patients with nonmedical needs, indi-
cating that extra time, education, and psychosocial support provided by the clinical
pharmacist is highly valued.
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1 | INTRODUCTION
From 1980 to 2012, the number of adults diagnosed with diabetes in
the United States nearly quadrupled from 5.5 million to 21.3 million1.
If this trend continues, as many as one in three adults in the US could
have diabetes by 2050, leading to a significantly increased disease
burden and cost to the US health care system.1,2 Diabetes is a com-
plex, chronic illness requiring a multifaceted, team-based approach to
care.3 Ongoing patient support and emphasis on self-management
skills are crucial to preventing complications and improving outcomes
in patients with diabetes. In this context, roles of clinical pharmacists
are expanding in the management of diabetes in the primary care set-
ting with the expanding role of the Patient Centered Medical Home
(PCMH) model.4,5
Clinical pharmacists are ideally suited to help primary care physi-
cians (PCPs) manage medications for patients diagnosed with type
2 diabetes mellitus (T2DM) who struggle to achieve glycemic control.
As defined by the American College of Clinical Pharmacy, clinical
pharmacy is a “health science discipline in which pharmacists provide
patient care that optimizes medication therapy and promotes health,
wellness, and disease prevention.”6 Clinical pharmacists can help
patients with poorly controlled T2DM overcome psychological insulin
resistance and other disease management barriers. Clinical pharma-
cists perform many additional professional interventions that are help-
ful for patients with diabetes and their prescribers, such as optimize
insulin and oral antidiabetic medication doses, monitor for side
effects, and assess and manage drug interactions.
Emerging evidence shows that clinical pharmacists can positively
impact T2DM-related outcomes. Multiple studies have demonstrated
that when pharmacists are added to the health care team in providing
diabetes management, an improvement in glycosylated hemoglobin
(A1C) is seen.4,7–9 Studies have demonstrated that collaborative man-
agement between PCPs and clinical pharmacists can lead to improved
blood pressure control, improved lipid profiles, decreased episodes of
hypoglycemia and emergency room visits, and increased preventative
services (eg, dilated eye exams, foot exams).4,9–15 Incorporating clini-
cal pharmacists into the care team has demonstrated cost savings and
improved quality-adjusted life years.16,17
An important component of patient-centered care is shared
decision-making characterized by effective patient-provider communi-
cation, where patients weigh treatment choices in light of the poten-
tial benefit and harm and arrive at informed preferences.18,19 While
current evidence is insufficient to fully assess the impact of PCMH
and shared decision-making19,23 on most quality and economic out-
comes, both PCMH20–22 and shared decision-making continue to hold
promise for improving the quality and cost-effectiveness of health
care. PCMH and shared decision-making are especially important in
the management of chronic diseases such as T2DM. Patients typically
develop long-term relationships with health care providers and, over
the progression of the disease, must repeatedly assess the pros and
cons of various medications and lifestyle changes to achieve treat-
ment goals.24–27
This quality interaction with patients, though recognized as value-
added care, can be time-consuming for PCPs working under a fee-for-
service reimbursement paradigm. However, clinical pharmacist
consultation is covered under care management benefits of many
commercial payers. The extra time allotted by this funding can be uti-
lized to educate patients on the importance of lifestyle modification
and how individual medications function to improve T2DM, and help
facilitate shared decision-making through close collaboration and fre-
quent contact with the patient.
Despite clinical pharmacists' success in medication therapy man-
agement and other disease-management activities, PCPs may be slow
or otherwise disinclined to refer patients. Factors contributing to this
delay could include a perceived lack of mandate, legitimacy, or effec-
tiveness of the specialty service;28 lack of knowledge on the appropri-
ate referral procedure;29 perceived lack of professionally constructive
communication between clinical pharmacists and PCPs;30 mispercep-
tions or negative biases toward the role of clinical pharmacists within
the primary care setting;31 concern about compensation/reimburse-
ment;32 lack of a trusting relationship with the ancillary providers (ie,
clinical pharmacists);32 discomfort with the potential impact the clinical
pharmacist could have on patients' overall medical follow-up;33 and
worry that the patient-physician relationship could be altered or
compromised.33
The data presented in this paper were drawn from a larger study
on patient and physician attitudes toward insulin initiation and the
role of the clinical pharmacist. Here, we aimed to answer several
questions targeted at PCP perceptions about patient disease manage-
ment needs and factors that are considered when deciding when to
refer patients to a clinical pharmacist for management of T2DM. In
particular, we address how PCPs determine whether to manage insu-
lin alone or refer to a clinical pharmacist or endocrinologist, and PCPs
perceptions regarding the clinical contribution of the endocrinologist
vs the clinical pharmacist. Additionally, we examined PCPs percep-
tions of factors that influence initiation of insulin therapy in poorly
controlled patients.
We anticipated that PCPs consider different factors when decid-
ing whether to refer patients to a clinical pharmacist vs an endocrinol-
ogist. The perceived contribution to patient disease management
from external subspecialist consultation vs clinical pharmacist under
the direction of the PCP is likely to depend on medical and social com-
plexity. These factors are patient-specific and would have to be con-
sidered on a case-by-case basis, but trends were expected to indicate
that PCPs prefer to keep patients within their practice if possible.
2 | METHODS
This was a qualitative survey of physician attitudes toward referral.
The physician sample was drawn from five University of Michigan
Department of Family Medicine (DFM) primary care clinics in and
around the Greater Ann Arbor, Michigan area. Together, these clinics
provide primary health care services to a diverse patient population,
with two clinics serving a mostly rural population, two serving a
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suburban population, and one a largely minority, socioeconomically
disadvantaged population. All sites host a clinical pharmacist for either
one or two 4-hour sessions per week. The clinical pharmacist has a
schedule that is managed by the clinical site, with 60 minutes allowed
for new patient consultations and 30 minutes for follow-up consulta-
tions. All DFM physicians were targeted for recruitment, with the
exception of those listed on the grant or who participated in a review
of questionnaires (n = 68). Advanced practice providers do not func-
tion as PCPs in our system, therefore they were not included in the
study.
This study was reviewed and approved by the University of Michi-
gan IRB (#HUM00084901). Funding for this project was provided by
the Blue Cross and Blue Shield of Michigan Foundation.
Investigators developed a questionnaire for this study. A
grounded, iterative revision process was employed, wherein study
investigators and an advisory panel of experienced physician
researchers piloted and modified the instrument over the course of
5 months and in excess of 11 iterations until 100% consensus on both
the instrument's content and layout was achieved. In its final form,
the instrument included 143 questions and required approximately
15-20 minutes to complete. The survey was sent by email to recruited
physicians, with a total of three reminders. Topics covered by the
instrument and analyzed here included demographics, assessing when
PCPs refer patients to a specialty or ancillary provider for care, factors
to consider when referring, and PCP perceptions regarding specialty
or ancillary providers' contribution to care. PCPs' perception of the
importance of 12 different factors to consider when referring patients
to an endocrinologist or clinical pharmacist was assessed using a
10-point scale ranging from not at all important to extremely impor-
tant. Clinical contributions of providers on six different items were
also measured using a five-point Likert scale ranging from strongly dis-
agree to strongly agree.
Demographics and PCPs responses to experience with specialty
providers and common practice of insulin initiation were assessed
using descriptive statistics. PCPs responses to A1C values and length
of time patients were poorly managed prior to referral were compared
between endocrinologist and clinical pharmacists using linear mixed
models to account for provider clustering. Clinical contributions and
importance of factors to consider when referring patients were com-
pared between clinical pharmacists and endocrinologists using paired
t tests.
3 | RESULTS
A total of 50 DFM physicians responded to the online survey,
resulting in a final response rate of 73.5%. Respondents were roughly
split between male and female (40% male, 60% female), and ranged in
years of experience. Approximately a third of the sample (29%) prac-
ticed for less than 5 years, 18% practiced for over 20 years, and the
rest were distributed between 6 and 10 years (17%), 11-15 years
(23%) and 16-20 years (13%). Most participants saw patients for at
least half of their working time (80%). The average number of adult
patients with T2DM seen during a typical clinic session was reported
at 2.19 (standard deviation [SD] = 0.97).
When asked about their practice when confronted with a patient
requiring insulin therapy, 66% of participants indicated that they usu-
ally initiate but sometimes refer patients to endocrine, clinical pharma-
cist, or other provider. Twenty-two percent indicated that they
sometimes initiate but usually refer patients to endocrine, clinical
pharmacist, or other provider. Only 4% indicated that they never initi-
ate insulin, and 8% indicated that they always initiate insulin
themselves.
The majority of PCPs indicated that they have referred patients to
endocrinologists (89.5%) and clinical pharmacists (93.5%) for T2DM,
whether it be for insulin initiation or other management. PCPs tended
to refer patients to clinical pharmacists sooner and at lower values of
A1C than to endocrinologists. Average A1C value at which partici-
pants indicated that they would refer patients to an endocrinologist
was 9.6% (SD = 0.9) and 8.4% (SD = 0.9) for clinical pharmacists
(P < 0.001). The average length of time that a patient had poorly con-
trolled diabetes before referral was reported to be 6.7 (SD = 3.1)
months for an endocrinologist and 4.8 (SD = 2.9) months for a clinical
pharmacist (P < 0.001).
Table 1 demonstrates that PCPs were more likely to refer patients
to clinical pharmacists if patients had higher comorbidity (P = 0.004), a
history of medical noncompliance (P = 0.001), low reading or math
skills (P < 0.001), more complex psychosocial situations (P < 0.001),
fear of needles (P < 0.001), and inability to meet medication and sup-
ply expense (P < 0.001). Table 2 shows the PCP perception of clinical
contribution of endocrinologists and clinical pharmacists. Participants
rated clinical pharmacists having a stronger contribution to the clinical
care of patients in all items.
4 | DISCUSSION
PCP perceptions indicated that T2DM patients working with a clinical
pharmacist had better disease control after the first visit. Access to
the clinical pharmacist and participating in team-based care were also
noted to be benefits. PCPs were more likely to refer patients with less
poorly controlled disease (lower A1C value) to a clinical pharmacist as
opposed to an endocrinologist, as well as patients with a shorter his-
tory of poor control. It is notable that PCPs found higher importance
when referring patients to the clinical pharmacist in patients with
higher nonmedical complexity, such as history of noncompliance, low
reading ability or math skill, complex psychosocial situation, being
afraid of needles, and difficulty meeting the expenses of medication
or supplies.
Patient self-management support is important in the care of
patients with T2DM and requires assessing and meeting the needs of
individual patients on a case-by-case basis. A variety of professions,
including clinical pharmacists, certified diabetes educators, and dieti-
cians can be included in the PCMH care team to meet the individual
needs of patients. Some patients may benefit more from the care of a
specialty provider. Our sample of physicians reported a large overlap
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in utilization of endocrinologist (89.5%) and clinical pharmacist
(93.7%) referrals. We hypothesized that referrals are made with care-
ful consideration of the needs of the patient. PCPs reported increased
utilization of clinical pharmacists for patients with nonmedical needs,
indicating that the extra time, education, and psychosocial support
provided by the clinical pharmacist is highly valued.
The majority (66%) of PCPs in our study reported that they usually
initiate insulin but sometimes refer patients to an endocrinologist or
clinical pharmacist, while another 22% reported that they sometimes
initiate insulin but usually refer patients. A recent study surveyed multi-
ple providers (endocrinologist, family physicians, internal medicine phy-
sicians, primary care nurse practitioners and physician assistants, and
pharmacists) to identify attitudes and practices regarding management
of T2DM found that PCPs lack confidence in prescribing insulin regi-
mens more complex than long acting insulin alone, and clinical pharma-
cists have an increased comfort in discussing long-acting basal insulin.34
Clinical pharmacists are ideally suited as permanent members of
the collaborative interprofessional team for patients with T2DM due
to their expertise in pharmacotherapy options, training in patient self-
management, and their emphasis on patient education. Clinical
pharmacists have a theoretical advantage given that they can offer
longer visits (or more time with the patient) and may be more accessi-
ble than PCPs or endocrinologists. These advantages were reflected
in PCP responses as physicians reported significantly better access to
care with a clinical pharmacist as opposed to an endocrinologist. The
importance of the clinical pharmacist as a valued member of the care
team was also notable. Patients were referred earlier and with a lower
A1C value than compared with endocrinologists. PCPs may value
reserving referrals to endocrinologists for patients with persistently
poorly controlled disease, as these specialists may be perceived as
better equipped to respond to increased medical complexity. In con-
trast, PCPs may value keeping less critical patients within their own
practice under the care of the clinical pharmacist perhaps because of
the longer visits and specialized training in facilitating goal-focused life-
style changes. Additionally, PCPs reported strong working relationships
and excellent communication with clinical pharmacists and felt that they
were active participants in the team-based approach to T2DM.
The University of Michigan has a robust clinical pharmacy program
with financial and administrative support from both the Medical
School and the College of Pharmacy. All adult primary care clinics
TABLE 1 Factors considered when referring patients to a clinical





mean (SD) P value
Excess weight gain is a
concern
3.3 (2.5) 2.7 (1.8) 0.13
The patient has multiple
comorbidities
5.9 (2.6) 4.6 (2.7) 0.004
The patient is medically frail 5.5 (2.7) 5.0 (2.4) 0.19
Congestive heart failure is a
concern
3.8 (2.3) 3.6 (2.2) 0.52
Kidney disease is a concern 4.7 (2.6) 4.1 (2.3) 0.17
Uncertainty about which
insulin to prescribe
6.0 (3.1) 5.2 (2.6) 0.11
The patient has a history of
noncompliance with medical
recommendations
7.2 (2.1) 5.8 (2.6) 0.001
The patient is emotionally
labile
3.5 (2.7) 2.7 (1.8) 0.14
The patient has very low
reading ability and/or math
skill
5.5 (2.6) 2.6 (2.0) <0.001
The patient has a complex
psychosocial situation
4.9 (2.9) 3.0 (1.9) <0.001
The patient reports being
afraid of needles
4.5 (2.8) 2.5 (1.7) <0.001
The patient has difficulty
meeting the expense of
medications and/or related
supplies (eg, test strips)
6.9 (2.5) 2.7 (1.9) <0.001
Abbreviation: SD, standard deviation. Bolded values are considered
significant.






mean (SD) P value
My patients with diabetes are
always able to access the P
when needed
4.0 (0.8) 2.9 (1.0) <0.001
I have a positive working
relationship with the P that
provides care to my patients
4.8 (0.5) 3.4 (0.8) <0.001
P provides excellent
communication to me about
the care they provide to my
patients
4.9 (0.4) 3.2 (0.9) <0.001
P's are active participants in
the team-based approach to
providing diabetes care—
that is, they work
collaboratively with patients
and the primary care
provider to accomplish
shared goals and to achieve
coordinated, high-quality
care
4.9 (0.3) 3.0 (0.8) <0.001
The time from referral to the P




4.3 (0.6) 2.5 (1.0) <0.001
Patients' control over their
disease is improved after
having seen the P
4.4 (0.5) 3.4 (0.6) <0.001
Abbreviation: SD, standard deviation. Bolded values are considered
significant.
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employ the services of a clinical pharmacist for 4 or 8 hours a week.
This availability drives referrals toward the clinical pharmacist within
the primary care site. Our PCPs practice in a large tertiary care health
system, with financial support for team members provided by com-
mercial and federal PCMH demonstration projects. However, embed-
ded clinical pharmacists may not be available or financially feasible by
many private PCPs, particularly in the current fee-for-service para-
digm. If primary care moves to a more comprehensive payment strat-
egy, incorporation of clinical pharmacists shows significant promise to
improve patient outcomes.
5 | CONCLUSION
This study demonstrated that PCPs value the contribution of the clini-
cal pharmacist as a member of the care team, and as a distinct entity
from endocrinologist specialty care. More research is needed to
further explore patients' perceptions of working with clinical pharma-
cists in the primary care setting, and the impact that clinical pharma-
cists have on overall attitudes towards managing T2DM. Future
directions could also include further quantifying the financial impact
of adding clinical pharmacists to the primary care team, as presumably
improving disease specific outcomes and avoiding disease complica-
tions via improved preventative measures and patient education
should result in significant cost savings, given the large financial
burden of caring for patients with T2DM. Additional investigations
could address whether a difference exists between providers of timing
of insulin initiation based upon uncontrolled disease and any resulting
cost savings.
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